Results 71 to 80 of about 72,150 (302)

Overall Survival in Advanced Stage Mantle Cell Lymphoma after Early Autologous Stem Cell Transplantation with Cisplatin, Etoposide, Cytarabine and Melphalan (PEAM) As a Conditioning Regimen [PDF]

, 2023
Daniel Franco, Fernando Tellez, Rubén Solís-Armenta, Araceli Leal Alanis, Carlos Cruz Castillo, Luis Manuel Valero Saldaña, Brenda L. Acosta‐Maldonado   +6 more
openalex   +1 more source

Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma

International Journal of Cancer, EarlyView.
What's New? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg, Ingrid Glimelius, Alexandra Albertsson‐Lindblad, Karin E. Smedby, Mats Jerkeman, Caroline E. Dietrich   +5 more
wiley   +1 more source

Influence of variability in starting materials quality on stability of finished drug products: a quality-by-design factor and response [PDF]

, 2012
The use of ill selected excipients in drug formulations can have a significant influence on the overall stability. Therefore, evaluation of chemical and physical excipient compatibility with the API has become a major part in the development of new drug ...
Bauters, Tieneke, D'Hondt, Matthias, De Spiegeleer, Bart, Robays, Hugo, Vandenbroucke, Johan, Wynendaele, Evelien   +5 more
core   +1 more source

Repurposing metformin for cancer treatment: current clinical studies. [PDF]

, 2016
In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer molecular mechanisms of metformin including mTOR inhibition, cytotoxic ...
Altman, Jessica K, Arya, Ayush, Carneiro, Benedito, Chae, Young Kwang, Chandra, Sunandana, Giles, Francis, Kalyan, Aparna, Kaplan, Jason, Malecek, Mary-Kate, Platanias, Leonidas, Shin, Daniel Sanghoon   +10 more
core   +1 more source

The hidden regulators: Non‐coding RNAs in KMT2A‐rearranged acute lymphoblastic leukemia

International Journal of Cancer, EarlyView.
Abstract Acute lymphoblastic leukemia (ALL) driven by KMT2A rearrangements (KMT2A‐r) is an aggressive hematologic malignancy with poor prognosis and a high incidence in infants. While KMT2A fusion proteins drive leukemogenesis through transcriptional dysregulation, recent discoveries have highlighted the pivotal role of non‐coding RNAs (ncRNAs) in ...
Maria Augusta Poersch, Ana Carolina Rodrigues, Priscila Elias Ferreira Stricker, Alexandre Luiz Korte Azevedo, Daniel Pacheco Bruschi, Jaqueline Carvalho de Oliveira   +5 more
wiley   +1 more source

Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches [PDF]

, 2014
The therapeutic strategies against acute myeloid leukemia (AML) have hardly been modified over four decades. Although resulting in a favorable outcome in young patients, older individuals, the most affected population, do not respond adequately to ...
Azevedo, Maria M., Castro, Isabel, Fernandes, Ângela Margarida Alves, Ludovico, Paula, Marques, Belém Sampaio, Neves, Margarida Correia, Paiva, Artur, Pereira, Olga   +7 more
core   +2 more sources

Efficacy and safety of stem cell mobilization with etoposide +cytarabine plus G-CSF in poor mobilizers with relapsed or refractory lymphoma

Frontiers in Immunology
BackgroundAutologous stem cell transplantation (ASCT) is a potentially curative strategy for relapse or refractory(r/r) aggressive lymphoma. However, a proportion of lymphoma patients who are at high risk of mobilization failure fail to mobilize stem ...
Zhijuan Zhu, Xiaofan Li, Xiaofan Li, Xiaohong Yuan, Xianling Chen, Ting Lin, Xiangli Guo, Nainong Li, Nainong Li   +8 more
doaj   +1 more source

Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study

International Journal of Cancer, EarlyView.
What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Xue Tang, Jing‐jing Sun, Zhi Wan, Xiao‐yu Jing, Xia Guo, Ju Gao   +5 more
wiley   +1 more source

Integrating Phase 2 into Phase 3 based on an Intermediate Endpoint While Accounting for a Cure Proportion -- with an Application to the Design of a Clinical Trial in Acute Myeloid Leukemia

, 2019
For a trial with primary endpoint overall survival for a molecule with curative potential, statistical methods that rely on the proportional hazards assumption may underestimate the power and the time to final analysis.
Heinzmann, Dominik, Monnet, Annabelle, Rufibach, Kaspar   +2 more
core   +1 more source

Analysis of Patients With Monocytic and Monocytic‐Like Acute Myeloid Leukemia, Including AML‐M4 and AML‐M5, Treated With Venetoclax Plus Azacitidine

American Journal of Hematology, EarlyView.
Marina Konopleva, Courtney D. DiNardo, Yan Sun, Paul Jung, Sanam Loghavi, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea   +8 more
wiley   +1 more source